Randomized, Stratified, Double-Blind, Placebo-Controlled Trial of Flumazenil and Gabapentin for the Treatment of Alcohol Dependence
Published in the Journal of Clinical Psychopharmacology, August 2009; 29(4):334-342.
The OnTrak Medical Treatment Program achieved a significant reduction in use and cravings among members with symptoms of alcohol withdrawal (>6 CIWA) when compared to placebo.
Among members with more symptoms of alcohol withdrawal, the Prometa group experienced:
• Promoted abstinence
• Reduced relapse
• Less heavy drinking days
• Less fatigue
• Improved mood
• Better sleep
• Medications were well tolerated
• The protocol may be ineffective for members who have fewer symptoms of alcohol withdrawal.